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Abstract 
Purpose: To investigate the efficacy of a double DNA vaccine encoding of Brucella melitensis omp31 
gene and of Escherichia coli eae gene in inducing protective immune response in a mouse model.  
Methods: After performing PCR assays and cloning both the eae and omp31 genes, the generated 
DNA vaccines were intramuscularly injected into BALB/c mice. Purified proteins and transformed cell 
lysates were identified by western blot and sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and analyzed by enzyme-linked immunosorbent assay (ELISA).  
Results: pcDNA3-omp31-eae provokes a significant, high level of protection in BALB/c mice against 
challenges with E. coli and B. melitensis. Titers ranging from 90:160 to 2,570:5,110 were detected 60 
days after vaccination. Notably, rOmp31 and rEae proteins significantly induced the production of IFN-γ 
in cells from pcDNA3-omp31-eae-immunized mice (p < 0.05 in both groups) and only low levels of IL-10 
were found in all groups. The lymphocytes from mice immunized with pcDNA3-omp31-eae had an 
apparent T cell proliferative response to rOmp31 and rEae proteins (p < 0.01) with a stimulation index of 
14.90.  
Conclusion: The novel pcDNA3-omp31-eae construct can be used as a DNA vaccine to prevent E. coli 
and B. melitensis infections in future studies. 
 
Keywords: Multiple DNA vaccine, Omp31 gene, Brucella melitensis, Eae gene, Escherichia coli, 
Protective immune response 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




DNA vaccines can induce both cellular and 
humoral immune responses, but have 
demonstrated only limited success in animals 
because of their low immunogenicity [1]. 
Nonetheless, DNA vaccines have several 
advantages over traditional protein-based 
vaccines, including induction of longer lasting 
immunity, ease of development, and lower 
production costs [2].  
 
One of the most widespread zoonoses, caused 
by the pathogenic bacterium Brucella, is 
brucellosis, a disease that affects humans and 
livestock. Brucella melitensis is an intracellular, 
facultative, Gram-negative bacterium that infects 
humans and a wide range of animals [3,4]. B. 
melitensis has high pathogenicity in humans and 
causes a large proportion of human cases [5,6]. 
Human brucellosis is treatable with antibiotics, 
but the course of antibiotic treatment must be 
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long because Brucella infections are intracellular 
[7]. Brucella species are therefore considered 
potential civilian, military, and agricultural 
bioterrorism agents [7]. In livestock, brucellosis 
can cause great economic losses, as infection 
can lead to stillbirths, abortions, and loss of 
fertility in animals [8,9].  
 
B. melitensis causes miscarriage in cows, goats, 
and sheep, and is considered to be the most 
pathogenic Brucella sp. for humans [10]. 
Recombinant Omp31 (rOmp31) vaccination 
elicits a CD4 Th1 response that provides partial 
protection against B. melitensis infections [11]. 
High concentrations of the plasmid containing the 
omp31 gene are needed to generate an efficient 
response, probably because of the low in vivo 
transfection efficiency for this type of plasmid 
vector [3]. 
 
Infections with Escherichia coli are commonly 
associated with diarrhea accompanied by bloody 
hemorrhagic colitis and abdominal cramps, but 
more serious complications such as thrombotic 
thrombocytopenic purpura, hemolytic-uremic 
syndrome, hemorrhagic colitis (HC), and in some 
cases, death, can also occur [12-14]. Pathogenic 
strains of E. coli are classified as either extra-
intestinal (ExPEC), causing a variety of infections 
in both animals and humans, or intestinal 
pathogens causing diarrhea [15]. The 
chromosomal gene eae, which encodes intimin, 
is part of a pathogenicity island termed the locus 
of enterocyte effacement (LEE) [13]. Eae is the 
first gene to be associated with attaching and 
effacing (AE) activity, and is essential for intimate 
bacterial attachment to eukaryotic host cells [14]. 
The eae gene is one of the genes currently used 
for the molecular diagnosis of enteropathogenic 
E. coli (EPEC) [16]. EPEC produces 
characteristic AE lesions on intestinal epithelial 
cells. The AE phenotype is encoded by a cluster 
of genes, including the eae gene located on the 
LEE [17]. The ability to cause AE lesions in 
enterocytes is the major virulence factor of E. coli 
in intestinal infections in humans and animals 
[18].  
 
The E. coli AE gene (eae) encodes a 94-kDa 
outer membrane protein, intimin, which is 
important but not sufficient for the production of 
AE lesions [18,19]. Inoculation with plasmid 
DNAs expressing foreign proteins stimulates 
both cellular and humoral immune responses 
that protect against bacteria, parasites, viruses, 
and tumors [20], and is a reasonably powerful 
and novel technique of immunization [21]. The 
aim of the present study is to investigate the 
immunogenicity and protective capacity of a DNA 
vaccine encoding the eae and omp31 proteins of 




Bacterial strains and DNA extraction 
 
B. melitensis and E. coli were obtained from the 
Microbiology Research Center of Islamic Azad 
University, Shahrekord Branch, Shahrekord, Iran. 
The B. melitensis and E. coli strains were grown 
on Brucella agar and Luria-Bertani (LB) agar, 
respectively. Genomic DNA was extracted using 
a Qiagen DNA extraction kit (Qiagen, Ltd., 
Crawley, UK). Quality was assessed according to 
manufacturer’s instructions by electrophoresing 
the extracted DNA on a 1 % agarose gel and 
measuring the optical density at 260 nm (OD 
260) d [22,23]. 
 
PCR amplification  
 
Specific oligonucleotide primers for the omp-31 
gene (omp31-F: 5'-ACCGGATCCACCACCATGA 
AATCCGTAATTTTG-3' and omp31-R: 5'-TGCTC 
GAGGAACTTGTAGTTCAGACCGAC-3') and the 
eae gene (eae-F: 5'-ACACTCGAGCAAACCAA 
GGCCAGCATTAC-3' and eae-R: 5'-CAGTCTA 
GATTATTCTACACAAACCGCAT-3') were 
designed and used in their respective 
amplification reactions. To amplify the omp31 
and eae genes, the 25-μL total volume PCR 
mixtures consisted of 2.5 µL 10× PCR buffer, 1 
μM each of the appropriate primers, 2 mM 
MgCl2, 200 μM dNTPs, 1 μg template cDNA, and 
1 unit pfu DNA polymerase (Roche Applied 
Science, Penzberg, Germany). For each gene, 
the 30-cycle amplification was performed in a 
thermal cycler system (Palm Cycler Gradient, 
Sydney, Australia) with their respective 
amplification programs are shown in Table 1. 
 
Table 1: Amplification program for omp31 gene 
 
Step Temperature (oC) 
Time 
(min) Cycle 
B. melitensis     
Initial denaturation 94 5 1 
Seg 1: 
Denaturation 
Seg 2: Annealing 








Final extension 72 5 1 
E. coli    
Initial denaturation 94 5 1 
Seg 1: 
Denaturation 
Seg 2: Annealing 








Final extension 72 5 1 
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Cloning of bacterial genes 
 
Electrophoresis was subsequently performed on 
a 1 % agarose gel in 1× TBE buffer, followed by 
staining with ethidium bromide and visualization 
on a UV transilluminator to verify the PCR 
product sizes. Bands corresponding to the 
omp31 and eae genes were cut from the gel and 
the DNA fragments were purified using a gel 
extraction kit (Bioneer, Cheongwon, Korea) 
according to the manufacturer’s instructions. 
TOPO-omp31 and TOPO-eae plasmids were 
cloned using the TA technique, as follows. 
Omp31 and eae DNA fragments were ligated to 
the T-vector using the TOPO T/A cloning kit 
(pCR8/GW/TOPO, Invitrogen, Carlsbad, 
California, United States) according to the 
manufacturer’s instructions, to obtain TOPO-
omp31 and TOPO-eae. BamHI/XhoI and 
XhoI/XbaI restriction analysis and PCR 
techniques were used to confirm insertion. The 
recombinant plasmids (TOPO-omp31 and 
TOPO-eae) were sequenced with specific 
primers using the Sanger method (Macrogen, 
Seoul, Korea), then linearized using BamHI/XhoI. 
The omp31 and eae genes were released from 
TOPO-omp31 and TOPO-eae, respectively, 
using BamHI/XhoI and XhoI/XbaI and inserted 
into the pcDNA3 plasmid. The pcDNA3-omp31-
eae plasmid constructs were verified by 
restriction digestion and sequencing. 
 
Preparation of recombinant omp31 and eae 
proteins 
 
To prepare recombinant Omp31 (rOmp31) and 
Eae (rEae) proteins, the omp31 and eae genes 
were excised from the pcDNA3-omp31-eae 
plasmid by BamHI/XhoI and XhoI/XbaI digestion 
and then inserted into the same restriction sites 
of the prokaryotic expression vector pET32a(+) 
(Novagen, Wisconsin, United States). The 
recombinant plasmids were transformed into E. 
coli BL21 (DE3) (Novagen). After culturing, the 
positive clones were selected. According to the 
manufacturer’s protocol, the recombinant 
proteins were expressed in successfully 
transformed bacteria by induction with isopropyl-
β-D-thiogalactopyranoside (IPTG) in LB medium 
and purified on a Ni2+-HiTrap chelating 5-mL pre-
packed column (Amersham Pharmacia Biotech, 
Piscataway, United States) using imidazole as 




The purified proteins and transformed cell lysates 
were identified by western blot and sodium 
dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE). Purified proteins were stored 
at –70 °C until use for in vitro stimulation of 
splenocytes or for enzyme-linked immunosorbent 
assays (ELISAs).  
 
In vivo analysis  
 
Mice were anesthetized by inhalation of 3 % 
halothane in 1 L/min fresh gas flow composed of 
an equal N2O:O2 mixture and maintenance in 1–
1.5 % halothane. The tibialis anterior muscle was 
then injected with 50 μg of plasmid DNA 
(pcDNA3-omp31-eae, 100 μg DNA/mouse) in 50 
μL of phosphate buffered saline (PBS) using a 
28-gauge needle insulin syringe. Mice were 
vaccinated at weeks 0, 2, and 4 with pcDNA3-
omp31-eae. As negative controls, separate 
groups of mice were immunized with pcDNA3, 
with PBS only, or with plasmid lacking either the 
omp31 or eae inserts. As a positive control, 
another group of mice was vaccinated 
intraperitoneally with 2 × 108 CFU of B. 
melitensis strain Rev 1 and E. coli in 0.2 mL 
PBS. 
 
Analysis of IgG isotypes 
 
The presence of serum immunoglobulin G (IgG) 
isotypes specific for rOmp31 and rEae was 
determined by indirect ELISA. pPurified rOmp31 
and rEae (3 μg mL-1 in carbonate buffer, pH 9.6) 
were added to standard polystyrene 96-well 
plates for ELISA (Nunc-Immuno plates with 
MaxiSorp, Nunk, Roskilde, Denmark), incubated 
overnight at 4 °C, then washed four times in 
wash buffer (Tris-buffered saline, pH 7.4, with 
0.05 % Tween 20). The plates were blocked with 
5 % gelatin in Tris-buffered saline at 37 °C for 2 
h, then incubated for 3 h at 24 °C and washed 
four times with serially diluted sera. Isotype-
specific rabbit anti-mouse horseradish 
peroxidase conjugates were added (ICN 
Biomedicals, Inc., Aurora, OH, USA) (50 μL well-
1) at appropriate dilutions. Plates were washed 
four times and 100 μL of substrate solution (200 
μmol of o-phenylenediamine and 0.04 % H2O2) 
was added to each well after 30 min, followed by 
incubation at 24 °C. The enzyme reaction was 
stopped after 20 min incubation at room 
temperature by the addition of 100 μL 0.18 M 
sulfuric acid, and the absorbance at 492 nm was 
measured. 
 
Mice were sacrificed two weeks after the last 
immunization and spleens were removed under 
aseptic conditions. After preparation of single-cell 
suspensions from the spleens, red blood cells 
were lysed with ACK solution (150 mM NH4Cl, 1 
mM KHCO3, 0.1 mM Na2·EDTA, pH 7.3). 
Splenocytes were cultured in 5 % CO2 at 37 °C 
at a concentration of 4 × 105 cells well-1 in RPMI 
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1640 medium supplemented with 2 mM L-
glutamine and 10 % heat-inactivated fetal calf 
serum (Sigma, St. Louis, United States) in a 96-
well flat-bottom plate in the presence of 0.08 μg 
purified rOmp31 and rEae protein or no additives 
(unstimulated control). Cells were cultured for 3 
days and pulsed for 8 h with 0.4 μCi of 3H-
thymidine (50 Ci mmol-1; Amersham Pharmacia 
Biotech) per well. Incorporated radioactivity was 
measured in a liquid scintillation counter. 
 
Cytokine detection and vaccine evaluation 
 
For cytokine detection, spleen cell culture 
supernatants were tested for the presence of 
cytokines by antigen-capture ELISA using 
OptEIA Set Mouse IFN-γ, IL-4, and IL-10 (BD 
Biosciences, San Diego, CA, USA) and collected 
after 48 h of antigen stimulation.  
 
Five weeks after vaccination, six mice from each 
group were challenged by intraperitoneal 
injection of 104 CFU of B. melitensis 16M or E. 
coli. After two weeks, the infected mice were 
sacrificed. Dilutions of spleen homogenate were 
plated to determine the number of E. coli and B. 
melitensis CFUs per spleen. This assay was 
performed in triplicate. Log10 units of protection 
were obtained by subtracting the mean log10 
CFU for the experimental group from the mean 




This work was approved by the ethical 
committees of the biotechnology research center, 
Islamic Azad University, Shahrekord, Iran and 
Research Adjutancy of the Islamic Azad 
University of Shahrekord (ref no. 2037550IAU). 
The laboratory animal studies followed 
international ethical and scientific guidelines on 




Amplified eae and omp31 genes  
 
The PCR amplified products for the B. melitensis 
omp31 and E. coli eae genes were respectively 
720 bp and 862 bp in length, as shown in Figure 
1. 
 
B. melitensis omp31 and E. coli eae genes were 
successfully cloned into TOPO vector. In 
addition, positive control colonies were obtained; 
matrix analyses of the cultured colonies for the 
omp31 and eae genes are shown in Figures 2 
and 3, respectively. 
 
Omp31 gene fragment, which has a BamHI/XhoI 
restriction site, and the eae gene fragment, which 
has a XhoI/XbaI restriction site, were inserted in 
the polyclonal site (PCS) of pCDNA3. The result 
of pcDNA3-omp31-eae restriction using 




Figure 1: Agarose gel electrophoresis of PCR-
amplified omp31 and eae gene products. Lane M: 
100-bp DNA marker, lane 1: negative control, lane 2: 





Figure 2: Detection of the B. melitensis omp31 gene 
in the cultured colony matrix by PCR. Lane M: 100-bp 
DNA marker, Lane 1: negative matrix sample, Lane 2: 
matrix 1, Lane 3: matrix 2, Lane 4: matrix 3, Lane 5: 




Figure 3: Detection of the E. coli eae gene in the 
cultured colony matrix by PCR. Lane M: 100-bp DNA 
marker, Lane 1: negative matrix sample, Lane 2: 
matrix 1, Lane 3: matrix 2, Lane 4: matrix 3, Lane 5: 
matrix 4, Lane 6: matrix 5 
 
Antibodies and immunological responses 
 
Immunization with pcDNA3-omp31-eae led to a 
rapid IgG response within two weeks after 
vaccination. Titers ranged from 90:160 to 
2,570:5,110; the peak titers were detected 60 
days after vaccination. IgG1 and IgG2a antibody 
analyses revealed that anti-Omp31 and anti-Eae  
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Figure 4: PcDNA3-omp31-eae restriction analysis. 
Lane M: 1-kb DNA marker, Lane 1: 5428-bp pcDNA3 
fragment and 862-bp eae fragment (correct clone), 
Lanes 2–3: 5428-bp pcDNA3 fragment without the eae 
gene 
 
antibodies were found in pcDNA3-omp31-eae 
immunized mice, but not those given pcDNA3. 
We determined the proliferation responses and 
cytokine profiles of spleen cells from mice 
injected with pcDNA3-omp31-eae, pcDNA3, and 
PBS to examine cell-mediated immunity (CMI). 
Lymphocytes from mice immunized with 
pcDNA3-omp31-eae had an apparent T cell 
proliferative response to rOmp31 and rEae 
proteins (p < 0.01) with a stimulation index of 
14.90.  
 
Cytokine profiles using supernatants of spleen 
cell cultures revealed higher levels of IFN-γ in 
pcDNA3-omp31-eae-immunized animals 
compared to the negative control groups. The 
rOmp31 and rEae proteins significantly induced 
the production of IFN-γ in cells from pcDNA3-
omp31-eae-immunized mice (p < 0.05 in both 
groups), and only low levels of IL-10 were found 
in all groups. In addition, no IL-4 was detected in 
culture supernatants of splenocytes that were 
stimulated with specific antigens.  
 
Protection tests were accomplished by 
challenging control and vaccinated mice with B. 
melitensis and E. coli and evaluating infection 
levels by determining CFU counts in the spleen. 
The results shown in Table 2 indicate that 
immunization with pcDNA3-omp31-eae resulted 
in a significantly higher degree of protection in 
comparison with the unimmunized control 
groups.  
 
Table 2: Comparison of stimulation by PBS, pcDNA3, 
and pcDNA3-omp31-eae in splenocyte cultures from 








γ IgG2a IgG1 
PBS - - - - - 
PcDNA3 - - - - - 
PcDNA3-
omp31-eae 
+ - +++ +++ ++ 
DISCUSSION 
 
DNA vaccines consisting of genes cloned into a 
eukaryotic plasmid are a novel and promising 
approach that can induce both humoral and 
cellular immune responses [25]. Control of 
Escherichia and Brucella has markedly reduced 
the incidence of human infection, but these 
diseases still represent an important cause of 
morbidity worldwide. To design a new generation 
of vaccines, more information on the antigenic 
makeup of Brucella and Escherichia spp. must 
be obtained to identify immunodominant proteins 
and epitopes. A human vaccine would be 
valuable for individuals who may be 
occupationally exposed to Brucella and 
Escherichia spp.  
 
Numerous attempts have been made to control 
human disease by vaccination with attenuated 
Brucella strains [21]. However, practical 
acceptance of these preparations has been very 
limited, mainly because of the unacceptable local 
inflammatory responses they elicit, combined 
with their limited protection. Obviously, there is a 
need for a better vaccine for brucellosis 
eradication [21]. Mice immunized with omp31 
were significantly protected against B. ovis and 
B. melitensis infections [3].  
 
Eae gene cloning results of the present study 
were similarly successful as those of for 
expression of the STX2 gene of E. coli O157:H7 
in pUC118 and pUC119 vectors [12] and of 
Hongyan et al [26]. Thus, our DNA construct can 
be used as a DNA vaccine against E. coli in 
future studies.  
 
The development of a safe and effective vaccine 
against B. melitensis and E. coli has proven to be 
complicated. Indeed, numerous intracellular and 
cell surface components have been assessed as 
protective antigens against these two bacterial 
infections, although only low or intermediate 
levels of protection have been achieved with 
these isolated proteins [9,12]. The B. melitensis 
omp31 and E. coli eae genes are promising 
candidates for use as a subunit vaccine against 
brucellosis and E. coli infection. In the case of B. 
melitensis and E. coli, cellular immune responses 
characterized by the production of IFN-γ are 
critical to conferring protection [27].  
 
In summary, this study demonstrates that DNA 
vaccines can be effective against E. coli and B. 
melitensis infections. In this study, we also 
assessed the capacity of pcDNA3-omp31-eae to 
elicit an immune response and protective 
immunity in BALB/c mice. Since the levels of 
protection achieved by a multiple DNA vaccine 
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encoding the omp31 gene of B. melitensis and 
the eae gene of E. coli are more than sufficient, 
this double DNA vaccine could be a useful 
candidate for the development of DNA vaccines 
against E. coli and B. melitensis infections. 
 
Limitations of the study 
 
DNA vaccines are limited to protein 
immunogens, that is, they can’t be used to confer 
immunity to non-protein based antigens such as 
bacterial polysaccharide. Induced antibody 
production against DNA may occur in the host 
organism. The achieved immune response in 
mice was satisfactory, but to obtain immunization 
in larger animals, high-level DNA doses are 
needed. In addition, insertion of foreign DNA into 
the host genome in order to obtain immune 




The DNA construct that was produced in this 
work can be further developed as a DNA vaccine 
against E. coli and B. melitensis. In addition, 
further studies are required to determine the 
functions of various T cell types in the protection 






The authors would like to thank Professor E 
Rahimi of the Department of Food Hygiene and 
Public Health, Islamic Azad University of 
Shahrekord, Iran, and Professor F 
Hemmatzadeh of the Department of Virology, 
Microbiology and Immunology, College of 
Science, University of Adelaide, Australia, for 
their technical support. This work was supported 
by the Biotechnology Research Center of Islamic 
Azad University of Shahrekord. 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 




1. Chen H, Gao N, Fan D, Wu J, Zhu J, Li J, et al. 
Suppressive effects on the immune response and 
protective immunity to a JEV DNA vaccine by co-
administration of a GM-CSF-expressing plasmid in mice. 
PLoS One 2012; 7(4): e34602. 
2. Oñate AA, Céspedes S, Cabrera A, Rivers R, González 
A, Muñoz C, et al. A DNA vaccine encoding Cu, Zn 
superoxide dismutase of Brucella abortus induces 
protective immunity in BALB/c mice. Infect Immun 2003; 
71(9): 4857-4861. 
3. Yang X, Hudson M, Walters N, Bargatze RF, Pascual 
DW. Selection of protective epitopes for Brucella 
melitensis by DNA vaccination. Infect Immun 2005; 
73(11): 7297-7303. 
4. Verger J-M, Grimont F, Grimont PA, Grayon M. Brucella, 
a monospecific genus as shown by deoxyribonucleic 
acid hybridization. Int J Syst Bacteriol 1985; 35(3): 292-
295. 
5. Li T, Yuan X, Ding J, Zhen Q, Ke Y, Wang Y, et al. 
Genome Sequence of Brucella melitensis Strain 128, an 
Isolate of Biovar 3 of Sequence Type 8. J Bacteriol 
2012; 194(24): 6960-6960. 
6. Bargen K, Gorvel J, Salcedo SP. Internal affairs: 
investigating the Brucella intracellular lifestyle. FEMS 
Microbiol Rev 2012; 36(3): 533-562. 
7. Halling SM, Peterson-Burch BD, Bricker BJ, Zuerner RL, 
Qing Z, Li L-L, et al. Completion of the genome 
sequence of Brucella abortus and comparison to the 
highly similar genomes of Brucella melitensis and 
Brucella suis. J Bacteriol 2005; 187(8): 2715-2726. 
8. Smither SJ, Perkins SD, Davies C, Stagg AJ, Nelson M, 
Atkins HS. Development and characterization of mouse 
models of infection with aerosolized Brucella melitensis 
and Brucella suis. Clin Vaccine Immunol 2009; 16(5): 
779-783. 
9. Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la 
Barrera S, Bowden Rl, et al.  Improved immunogenicity 
of a vaccination regimen combining a DNA vaccine 
encoding Brucella melitensis outer membrane protein 31 
(Omp31) and recombinant Omp31 boosting. Clin 
Vaccine Immunol 2007; 14(7): 869-874. 
10. Young EJ. An overview of human brucellosis. Clin Infect 
Dis 1995; 21(2): 283-289. 
11. Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati 
CA, Baldi PC. Antibody reactivity to Omp31 from 
Brucella melitensis in human and animal infections by 
smooth and rough Brucellae. Clin Diagn Lab Immunol 
2004; 11(1): 111-114. 
12. Doosti A, Kargar M, Golshan M. Cloning of Stx2 B 
Subunit Gene from Enterohemorrhagic Escherichia coli 
O157: H7 to the Expression Vector (pCDNA 3.1+) as 
DNA Vaccine Candidate. Middle East J Sci Res 2011; 
9(5): 616-620. 
13. Blanco M, Blanco JE, Mora A, Dahbi G, Alonso MP, 
González EA, et al. Serotypes, virulence genes, and 
intimin types of Shiga toxin (verotoxin)-producing 
Escherichia coli isolates from cattle in Spain and 
identification of a new intimin variant gene (eae-ξ). J Clin 
Microbiol 2004; 42(2): 645-651. 
Ranjbar et al 
Trop J Pharm Res, October 2016; 15(10): 2083  
 
14. Shariati Mehr K, Mousavi SL, Rasooli I, Amani J, Rajabi 
M. A DNA Vaccine against Escherichia coli O157: H7. 
Iran Biomed J 2012; 16(3): 139-133. 
15. Kaper JB, Nataro JP, Mobley HLT. Pathogenic 
escherichia coli. Nat Rev Microbiol 2004, 2(2): 123-140. 
16. Jafari A, Aslani MM, Bouzari S. Escherichia coli: a brief 
review of diarrheagenic pathotypes and their role in 
diarrheal diseases in Iran. Iran J Microbiol 2012; 4(3): 
102. 
17. Miyajima Y, Matui Y, Adachi R, Yamamoto K, Saito T, 
Kobayashi G, et al.  Serotyping and molecular 
characterization of eae-positive Escherichia coli isolated 
in a gastroenteritis outbreak. Jpn J Infect Dis 2011; 64: 
351-352. 
18. Wieler LH, Vieler E, Erpenstein C, Schlapp T, Steinrück 
H, Bauerfeind R, et al. Shiga toxin-producing 
Escherichia coli strains from bovines: association of 
adhesion with carriage of eae and other genes. J Clin 
Microbiol 1996; 34(12): 2980-2984. 
19. Amani J, Mousavi SL, Rafati S, Salmanian AH. 
Immunogenicity of a plant-derived edible chimeric EspA, 
Intimin and Tir of Escherichia coli O157: H7 in mice. 
Plant Sci 2011; 180(4): 620-627. 
20. Gurunathan S, Wu C-Y, Freidag BL, Seder RA. DNA 
vaccines: a key for inducing long-term cellular immunity. 
Curr Opin Immunol 2000; 12(4): 442-447. 
21. Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, 
Bruno L, Bowden Rl, et al.  A DNA vaccine coding for 
the Brucella outer membrane protein 31 confers 
protection against B. melitensis and B. ovis infection by 
eliciting a specific cytotoxic response. Infect Immun 
2005; 73(10): 6537-6546. 
22. Doosti A, Arshi A, Sadeghi M. Investigation of Coxiella 
burnetii in Iranian camels. Comp Clin Path 2014; 23(1): 
43-46. 
23. Saeidi E, Sheikhshahrokh A. vacA Genotype Status of 
Helicobacter pylori Isolated from Foods with Animal 
Origin. Biomed Res Int 2016; 2016. 
24. Ferdowsian HR, Beck N. Ethical and scientific 
considerations regarding animal testing and research. 
PloS one 2011; 6(9): e24059. 
25. Moreno S, Timon M. DNA vaccination: an immunological 
perspective. Immunol 2004; 123: 41-55. 
26. An H, Fairbrother JM, Dubreuil JD, Harel Je. Cloning and 
characterization of the eae gene from a dog attaching 
and effacing Escherichia coli strain 4221. FEMS 
Microbiol Lett 1997; 148(2): 239-245. 
27. Doosti A, Dehkordi PG, Javadi G-R, Sardari S, 
Shokrgozar MA. DNA vaccine encoding the Omp31 
gene of Brucella melitensis induces protective immunity 
in BALB/c mice. Res J Biol Sci 2009; 4(1): 126-131. 
 
